A Phase 1, open-label, randomized, crossover study in healthy adult subjects to assess the relative oral bioavailability and food effect of a single 250-mg dose of JNJ-53718678 administered as oral solid concept formulation compared to a suspension and the effect of storage conditions of the suspension on the pharmacokinetics of JNJ-53718678
Latest Information Update: 27 May 2021
At a glance
- Drugs Rilematovir (Primary) ; Rilematovir (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Sponsors Janssen Sciences Ireland UC
Most Recent Events
- 03 Mar 2021 This trial has been completed in Belgium according to European Clinical Trials Database record.
- 03 Mar 2021 This trial has been completed in Belgium according to European Clinical Trials Database record.
- 28 May 2020 New trial record